Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-22
2000-01-11
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142282, 514323, 514414, 514419, 544 585, 544143, 544144, 546201, 548465, 548468, 548493, A61K 31405, A61K 31535, C07D20912, C07D41306
Patent
active
060136480
ABSTRACT:
The use of human CB.sub.2 receptor-specific agonists of formula (I) or (I') for preparing immunomodulating drugs is disclosed. In formulae (I) and (I'), R.sub.1 is a group selected from --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11, --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11, --CHR.sub.9 CH.sub.2 NR'.sub.6 R'.sub.11, --(CH.sub.2).sub.n Z and --COR.sub.8 ; R'.sub.1 is a --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11 or --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11 group; R.sub.2 and R'.sub.2 are hydrogen, halogen or C.sub.1-4 alkyl; R.sub.3 is hydrogen, C.sub.1-4 alkyl or a group selected from --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11, --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11 and --COR.sub.8 ; R'.sub.3 is a .dbd.CR.sub.6 R.sub.8 group; R.sub.4 has one of the meanings given for R.sub.5 or is a --COR.sub.8 group; R.sub.5 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, a halogen atom, a CF.sub.3 group, an OCF.sub.3 group or C.sub.1-4 alkylthio; R'.sub.5 has one of the meanings given for R.sub.5 and is in the 5 or 6 position of the indene ring; R.sub.6 is hydrogen or C.sub.1-4 alkyl; R'.sub.6 is C.sub.1-4 alkyl; R.sub.7 has one of the meanings given for R.sub.5 or R.sub.7 and R.sub.9 together form a --Y--CH.sub.2 -- group attached to the indole ring in the 7 position by a group Y; R.sub.8 is phenyl substituted one to four times by a substituent selected from halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy; a polycyclic ring selected from naphth-1-yl, naphth-2-yl, 1,2,3,4-tetrahydronaphth-1-yl, 1,2,3,4-tetrahydronaphth-5-yl, anthryl, benzofuryl, benzothien-2-yl, benzothien-3-yl, 2-, 3-, 4- or 8-quinolyl, said polycyclic rings optionally being substituted once or twice by a substituent selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halogen, cyano, hydroxyl, trifluoromethyl and imidazol-1-yl; R.sub.10 and R.sub.11 together are a group selected from --CH.sub.2 --O--CH.sub.2 --CR.sub.12 R.sub.13 -- and --(CH.sub.2).sub.p --CR.sub.12 R.sub.13 --, wherein the carbon atom substituted by R.sub.12 and R.sub.13 is attached to the nitrogen atom; R'.sub.11 is C.sub.1-4 alkyl; or R'.sub.11 and R'.sub.6, taken together with the nitrogen atom to which they are attached, form a group selected from morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl and pyrrolidin-1-yl; each of R.sub.12 and R.sub.13 is independently hydrogen or C.sub.1-4 alkyl; n is 2, 3, 4 or 5; p is 2 or 3; Z is a methyl group or a halogen atom; and Y is a methylene group or an oxygen atom.
REFERENCES:
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
Kaminski, Adv. Exp. Med. Biol.,335:115-120 (1993).
D'Ambra et al., Journal of Medicinal Chemistry, 35:124-135 (1992).
Chemical Abstracts, vol. 99, No. 25, Dec. 19, 1983 (Sarbu et al., Descrierea Inventiei 77049).
Chemical Abstract, vol. 107, No. 15, Oct. 12, 1987 (Sarbu et al. Descrierea Inventiei 90049).
Sarbu et al., Rev. Roum. Chim., 25: 245-251 (1980).
Huffman et al., Bioorg. Med. Chem. Lett., 4: 563-566 (1994).
Bell et al., J. Med. Chem., 34: 1110-1116 (1991).
Pacheco et al., J. Pharmacol. Exp. Ther., 257: 170-183 (1991).
Chemical Abstracts, vol. 124, No. 17, 1425 (1996) (D'Ambra et al., Bioorg. Med. Chem. Lett., 6.
Chemical Abstracts, vol. 123, No. 3, 59-60 (1995) (Pertwee et al., Life Sci., 56: 23/24 (1995)).
Yamada et al., J. Med. Chem., 39: 1967-1974 (1996).
Eissenstat et al., J. Med Chem., 38: 3094-3105 (1995).
Derocq et al., Febs Letters, 369: 177-182 (1995).
Barth Francis
Bell Malcolm R.
Casellas Pierre
Congy Christian
D'Ambra Thomas E.
Raymond Richard L.
Sanofi
LandOfFree
CB.sub.2 Receptor agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CB.sub.2 Receptor agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CB.sub.2 Receptor agonist compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462530